Indication Aimovig® (erenumab-aooe) is indicated for the preventive treatment of migraine in adults.
Aimovig® is indicated for the preventive treatment of migraine in adults. Aimovig® is the first-approved anti–calcitonin gene-related peptide pathway treatment for migraine prevention.1
Aimovig®—a therapy specifically designed to help prevent migraine1
Aimovig® selectively targets and blocks the calcitonin gene-related peptide receptor (CGRP-R), disrupting a key component of migraine pathophysiology.1,2
The CGRP neuropeptide activates the CGRP receptor3,4
CGRP-R is located at sites that
are relevant to migraine
pathophysiology.3,4
The activation of CGRP receptors is believed to contribute to migraine2-4
Levels of CGRP have been shown to increase during a migraine attack.2-4
Aimovig® targets and blocks the CGRP receptor1,5
Aimovig® is a fully human monoclonal antibody that binds potently and selectively to the CGRP receptor to inhibit its function.1,5
The recommended dosage of Aimovig® is 70 mg once monthly; some patients may benefit from 140 mg once monthly.1
The most common adverse reactions in clinical studies (≥3% of Aimovig®-treated patients and more often than placebo) were injection site reactions and constipation.1 Learn about Aimovig® safety data.
Please see Aimovig® full Prescribing Information.
The list price of Aimovig® is $767.67 per month.* Most patients do not pay the list price. A patient’s actual cost will vary. They should talk to their insurance provider.
*List price is also referred to as wholesale acquisition cost, or WAC. WAC is the price at which Amgen sells its products to wholesalers.
Updated on Jan 08, 2025.
Yes. Your eligible commercially insured patients may pay as little as $5* out-of-pocket per month with the Aimovig® Co-Pay Card.
*Eligibility criteria and program maximums apply. Terms and conditions apply. Please see summary of the full Terms and Conditions below.
Amgen® SupportPlus can provide your patients with information about independent nonprofit foundations that may be able to help.* Learn more about how Amgen® SupportPlus can help your patients access their prescribed medication.
*Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofit’s criteria. Amgen has no control over these programs and provides information as a courtesy only.
Your patient’s health plan may require a prior authorization (PA) before approving Aimovig®. Download these resources to help your patients secure access to their treatment:
Use these resources to help your patients inject Aimovig® on their own:
In addition to co-pay support, Amgen® SupportPlus offers resources to help your patients along their treatment journey:
A simple way for patients to get support and resources during their first 3 months of treatment
Patients receive a text message when it’s time for a refill
Patients can track their monthly migraine days by responding to a text
As of June 20, 2025, Aimovig® no longer provides samples. However, we remain committed to helping patients access their prescribed medication. Learn more about our patient support program and resources, including a quick start guide, how to sign up for the Aimovig®
Co-Pay Card, and more.
No. The Aimovig® Co-Pay Card Program is offered through Amgen® SupportPlus for eligible commercially insured patients. Visit AmgenSupportPlus.com to learn more.
Encourage your patients to call 1-833-AIMOVIG (1-833-246-6844), Monday–Friday, 8:00 AM–8:00 PM ET.
SUMMARY OF TERMS AND CONDITIONS
It is important that every patient read and understand the full Aimovig® (erenumab-aooe) Co-Pay Card Terms and Conditions. The following summary is not a substitute for reviewing the Terms and Conditions in their entirety.
As further described in the full terms and conditions, in general:
Please see the full Terms and Conditions at aimovig.com/toc.
Contraindication: Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.
Hypersensitivity Reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig® in post marketing experience. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. If a serious or severe reaction occurs, discontinue Aimovig® and initiate appropriate therapy.
Constipation with Serious Complications: Constipation with serious complications has been reported following the use of Aimovig® in the postmarketing setting. There were cases that required hospitalization, including cases where surgery was necessary. The onset of constipation was reported after the first dose in a majority of these cases, but patients also reported later on in treatment. Aimovig® was discontinued in most reported cases. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies.
Monitor patients treated with Aimovig® for severe constipation and manage as clinically appropriate. Concurrent use of medications associated with decreased gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications.
Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of Aimovig® in the postmarketing setting. Many of the patients had pre-existing hypertension or risk factors for hypertension. There were cases requiring pharmacological treatment and, in some cases, hospitalization. Hypertension may occur at any time during treatment but was most frequently reported within seven days of dose administration. In the majority of the cases, the onset or worsening of hypertension was reported after the first dose. Aimovig® was discontinued in many of the reported cases.
Monitor patients treated with Aimovig® for new-onset hypertension, or worsening of pre-existing hypertension, and consider whether discontinuation of Aimovig® is warranted if evaluation fails to establish an alternative etiology.
Raynaud's Phenomenon: Development of Raynaud’s phenomenon and recurrence or worsening of preexisting Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists, including AIMOVIG. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain.
AIMOVIG should be discontinued if signs or symptoms of Raynaud’s phenomenon develop, and patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud’s phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms.
Adverse Reactions: The most common adverse reactions in clinical studies (≥ 3% of Aimovig®-treated patients and more often than placebo) were injection site reactions and constipation.
Aimovig® (erenumab-aooe) is indicated for the preventive treatment of migraine in adults.
Please see Aimovig® full Prescribing Information.
Contraindication: Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.
Hypersensitivity reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig® in post marketing experience. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. If a serious or severe
References: 1. Aimovig. Package insert. Amgen Inc; 2025. 2. Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol. 2015;55:533-552. 3. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553-622. 4. Raddant AC, Russo AF. Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev Mol Med. 2011;13:e36. doi:10.1017/S1462399411002067. 5. Shi L, Lehto SG, Zhu DX, et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther. 2016;356(1):223-231.
COVERAGE & SUPPORT
